The trial is the culmination of a pioneering research programme to
design, synthesise and develop the new drug class, led by scientists at
The Institute of Cancer Research, London, and the Cancer Research UK
Manchester Institute at The University of Manchester.
It is starting just three months after a major publication in the journal Cancer Cell described the potential of this new drug class, which is potentially able to treat Melanomas, the most serious type of skin cancer, that do not respond or have become resistant to existing therapies.
The
phase I trial of the drug, which is yet to be given a formal name and
is currently known as BAL3833/CCT3833, is sponsored by The Institute of
Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust. The
trial is funded by the Wellcome Trust, the NIHR Biomedical Research
Centre at The Royal Marsden and the ICR, The Christie charity and the
Cancer Research UK Manchester Institute. The first
patient began treatment at The Royal Marsden, with patients also to be
treated at The Christie NHS Foundation Trust in Manchester.
Just
last month, a new consortium was announced to develop this drug class
for patients, following an agreement between academic organisations,
funders and Swiss-based biopharmaceutical company Basilea Pharmaceutica
International Ltd.
The trial will recruit around 25 patients with advanced, solid tumors, focusing on advanced Melanoma, with the aim of establishing the safe maximum dose for a planned phase II clinical trial.
No comments:
Post a Comment